vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and PRA GROUP INC (PRAA). Click either name above to swap in a different company.
PRA GROUP INC is the larger business by last-quarter revenue ($333.4M vs $263.6M, roughly 1.3× BALCHEM CORP). PRA GROUP INC runs the higher net margin — 17.0% vs 14.9%, a 2.1% gap on every dollar of revenue. On growth, PRA GROUP INC posted the faster year-over-year revenue change (13.7% vs 9.8%). Over the past eight quarters, PRA GROUP INC's revenue compounded faster (14.2% CAGR vs 4.9%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
PRA Group, Inc. is a publicly traded debt buyer and debt collection company based in Norfolk, Virginia. The company buys delinquent consumer debt from credit card issuers and other financial institutions at a discount and pursues collection of the full debt owed. Founded in 1996, PRA Group employs more than 3200 people in 18 countries.
BCPC vs PRAA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $263.6M | $333.4M |
| Net Profit | $39.2M | $56.5M |
| Gross Margin | 35.6% | — |
| Operating Margin | 19.8% | 37.7% |
| Net Margin | 14.9% | 17.0% |
| Revenue YoY | 9.8% | 13.7% |
| Net Profit YoY | 16.8% | 206.3% |
| EPS (diluted) | $1.21 | $1.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $263.6M | $333.4M | ||
| Q3 25 | $267.6M | $311.1M | ||
| Q2 25 | $255.5M | $287.7M | ||
| Q1 25 | $250.5M | $269.6M | ||
| Q4 24 | $240.0M | $293.2M | ||
| Q3 24 | $239.9M | $281.5M | ||
| Q2 24 | $234.1M | $284.2M | ||
| Q1 24 | $239.7M | $255.6M |
| Q4 25 | $39.2M | $56.5M | ||
| Q3 25 | $40.3M | $-407.7M | ||
| Q2 25 | $38.3M | $42.4M | ||
| Q1 25 | $37.1M | $3.7M | ||
| Q4 24 | $33.6M | $18.5M | ||
| Q3 24 | $33.8M | $27.2M | ||
| Q2 24 | $32.1M | $21.5M | ||
| Q1 24 | $29.0M | $3.5M |
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.5% | — | ||
| Q1 24 | 34.0% | — |
| Q4 25 | 19.8% | 37.7% | ||
| Q3 25 | 20.4% | -101.4% | ||
| Q2 25 | 20.1% | 29.6% | ||
| Q1 25 | 20.4% | 27.7% | ||
| Q4 24 | 19.8% | 32.1% | ||
| Q3 24 | 20.0% | 32.0% | ||
| Q2 24 | 19.6% | 31.4% | ||
| Q1 24 | 17.4% | 26.0% |
| Q4 25 | 14.9% | 17.0% | ||
| Q3 25 | 15.1% | -131.0% | ||
| Q2 25 | 15.0% | 14.7% | ||
| Q1 25 | 14.8% | 1.4% | ||
| Q4 24 | 14.0% | 6.3% | ||
| Q3 24 | 14.1% | 9.6% | ||
| Q2 24 | 13.7% | 7.6% | ||
| Q1 24 | 12.1% | 1.4% |
| Q4 25 | $1.21 | $1.47 | ||
| Q3 25 | $1.24 | $-10.43 | ||
| Q2 25 | $1.17 | $1.08 | ||
| Q1 25 | $1.13 | $0.09 | ||
| Q4 24 | $1.03 | $0.47 | ||
| Q3 24 | $1.03 | $0.69 | ||
| Q2 24 | $0.98 | $0.54 | ||
| Q1 24 | $0.89 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $74.6M | $104.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $979.9M |
| Total Assets | $1.7B | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $104.4M | ||
| Q3 25 | $65.1M | $107.5M | ||
| Q2 25 | $65.4M | $131.6M | ||
| Q1 25 | $49.9M | $128.7M | ||
| Q4 24 | $49.5M | $105.9M | ||
| Q3 24 | $73.7M | $141.1M | ||
| Q2 24 | $63.7M | $118.9M | ||
| Q1 24 | $60.3M | $108.1M |
| Q4 25 | $1.3B | $979.9M | ||
| Q3 25 | $1.3B | $928.5M | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.2B | $1.2B | ||
| Q4 24 | $1.1B | $1.1B | ||
| Q3 24 | $1.2B | $1.2B | ||
| Q2 24 | $1.1B | $1.1B | ||
| Q1 24 | $1.1B | $1.1B |
| Q4 25 | $1.7B | $5.1B | ||
| Q3 25 | $1.7B | $5.0B | ||
| Q2 25 | $1.7B | $5.4B | ||
| Q1 25 | $1.6B | $5.1B | ||
| Q4 24 | $1.6B | $4.9B | ||
| Q3 24 | $1.6B | $4.9B | ||
| Q2 24 | $1.6B | $4.7B | ||
| Q1 24 | $1.6B | $4.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $67.3M | $-85.5M |
| Free Cash FlowOCF − Capex | — | $-90.4M |
| FCF MarginFCF / Revenue | — | -27.1% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | 1.72× | -1.51× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-169.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $67.3M | $-85.5M | ||
| Q3 25 | $65.6M | $-10.1M | ||
| Q2 25 | $47.3M | $-12.9M | ||
| Q1 25 | $36.5M | $-52.6M | ||
| Q4 24 | $52.3M | $-94.6M | ||
| Q3 24 | $51.3M | $-35.0M | ||
| Q2 24 | $45.0M | $-29.5M | ||
| Q1 24 | $33.4M | $-73.0M |
| Q4 25 | — | $-90.4M | ||
| Q3 25 | — | $-11.3M | ||
| Q2 25 | — | $-14.2M | ||
| Q1 25 | — | $-53.5M | ||
| Q4 24 | — | $-98.6M | ||
| Q3 24 | — | $-36.1M | ||
| Q2 24 | — | $-30.8M | ||
| Q1 24 | — | $-73.5M |
| Q4 25 | — | -27.1% | ||
| Q3 25 | — | -3.6% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -19.8% | ||
| Q4 24 | — | -33.6% | ||
| Q3 24 | — | -12.8% | ||
| Q2 24 | — | -10.8% | ||
| Q1 24 | — | -28.8% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | — | 0.4% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | 1.72× | -1.51× | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 1.23× | -0.30× | ||
| Q1 25 | 0.98× | -14.37× | ||
| Q4 24 | 1.56× | -5.13× | ||
| Q3 24 | 1.52× | -1.29× | ||
| Q2 24 | 1.40× | -1.37× | ||
| Q1 24 | 1.15× | -21.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
PRAA
| GB | $170.1M | 51% |
| Other | $163.3M | 49% |
